Dexcom

At the Wells Fargo conference, Dexcom announced a growth plan based on expanded reimbursement (Medicare for non‑insulin‑treated type‑2 patients by mid‑2027), new products including a 15‑day sensor, and a software/AI push. The 15‑day sensor is expected to reach about 50% of the US G‑Series user base by the end of 2026; Stelo generates quarterly revenue of roughly $35–42 million and will be expanded with an AI coach. In the near term management expects margin pressure from the production ramp in Ireland and transitions; long term Dexcom targets annual growth of over 10% through 2029 and margin expansion of roughly 150 basis points versus 2025. The company reaffirms its 2026 guidance and sees major opportunities in expanding CGM use among non‑insulin‑treated type‑2 patients. » More on de.investing.com

DexCom shares hit a new 52-week high of $91.99 and are up about 36% year-to-date. In the second quarter, DexCom reported revenue of $1.308 billion, a 13% increase compared with the prior year, and raised its guidance for the second time. Analysts such as RBC, BTIG and Canaccord raised price targets, Piper Sandler reiterated "overweight" and TD Cowen reaffirmed "buy" after DexCom was included in the FDA TEMPO pilot program. » More on de.investing.com

DexCom's stock rose to a 52-week high of $87.85 and is currently trading at $87.73, about 1% below the record. The share price is up 27.69% year-to-date; market capitalization is $33.06 billion. In the second quarter DexCom reported revenue of $1.308 billion (+13.1% year-over-year), beat consensus estimates and raised its guidance for the second time. Several analysts raised price targets, and DexCom was selected for the FDA TEMPO pilot program, supporting the positive market momentum. » More on de.investing.com